Relationships between PET and blood plasma biomarkers in corticobasal syndrome.
blood plasma biomarkers
corticobasal syndrome
positron emission tomography uptake
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
revised:
26
04
2024
received:
22
02
2024
accepted:
28
04
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
Corticobasal syndrome (CBS) can result from underlying Alzheimer's disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker-confirmed AD in CBS. A cohort of eighteen CBS patients (8 amyloid beta [Aβ]+; 10 Aβ-) and 8 cognitively unimpaired (CU) individuals underwent PET imaging and plasma analysis. Plasma concentrations were compared using a Kruskal-Wallis test. Spearman correlations assessed relationships between plasma concentrations and PET uptake. CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ- group only showed elevated NfL concentration compared to CU. Both p-tau181 and GFAP were able to differentiate CBS Aβ- from CBS Aβ+ and showed positive associations with Aβ and tau PET uptake. This study supports use of plasma p-tau181 and GFAP to detect AD in CBS. NfL shows potential as a non-specific disease biomarker of CBS regardless of underlying pathology. Plasma phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) concentrations differentiate corticobasal syndrome (CBS) amyloid beta (Aβ)- from CBS Aβ+. Plasma neurofilament light concentrations are elevated in CBS Aβ- and Aβ+ compared to controls. Plasma p-tau181 and GFAP concentrations were associated with Aβ and tau positron emission tomography (PET) uptake. Aβ42/40 ratio showed a negative correlation with Aβ PET uptake.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : R01-AG50603
Pays : United States
Organisme : NIH HHS
ID : R01-NS089757
Pays : United States
Organisme : NIH HHS
ID : R01-DC12519-06
Pays : United States
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496‐503. doi:10.1212/WNL.0b013e31827f0fd1
Kertesz A, Martinez‐Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 2000;55(9):1368‐1375. doi:10.1212/wnl.55.9.1368
McMonagle P, Blair M, Kertesz A. Corticobasal degeneration and progressive aphasia. Neurology. 2006;67(8):1444‐1451. doi:10.1212/01.wnl.0000240215.43492.01
Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327‐340. doi:10.1002/ana.22424
Shir D, Pham NTT, Botha H, et al. Clinicoradiologic and neuropathologic evaluation of corticobasal syndrome. Neurology. 2023;101(3):e289‐e299. doi:10.1212/WNL.0000000000207397
Boyd CD, Tierney M, Wassermann EM, et al. Visuoperception test predicts pathologic diagnosis of Alzheimer disease in corticobasal syndrome. Neurology. 2014;83(6):510‐519. doi:10.1212/WNL.0000000000000667
Ouchi H, Toyoshima Y, Tada M, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord. 2014;29(2):238‐244. doi:10.1002/mds.25746
Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re‐evaluation. Brain. 2010;133(Pt 7):2045‐2057. doi:10.1093/brain/awq123
Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord. 2009;24(11):1593‐1599. doi:10.1002/mds.22558
Nakano Y, Hirano S, Kojima K, et al. Dopaminergic correlates of regional cerebral blood flow in Parkinsonian disorders. Mov Disord. 2022;37(6):1235‐1244. doi:10.1002/mds.28981
de Almeida IJ, Silagi ML, Carthery‐Goulart MT, et al. The discourse profile in corticobasal syndrome: a comprehensive clinical and biomarker approach. Brain Sci. 2022;12(12):1705. doi:10.3390/brainsci12121705
Goodheart AE, Locascio JJ, Samore WR, et al. 18F‐AV‐1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. Brain. 2021;144(1):266‐277. doi:10.1093/brain/awaa383
Parmera JB, de Almeida IJ, de Oliveira MCB, et al. Metabolic and structural signatures of speech and language impairment in corticobasal syndrome: a multimodal PET/MRI study. Front Neurol. 2021;12:702052. doi:10.3389/fneur.2021.702052
Palleis C, Brendel M, Finze A, et al. Cortical [(18) F]PI‐2620 binding differentiates corticobasal syndrome subtypes. Mov Disord. 2021;36(9):2104‐2115. doi:10.1002/mds.28624
Benvenutto A, Guedj E, Felician O, et al. Clinical phenotypes in corticobasal syndrome with or without amyloidosis biomarkers. Journal of Alzheimers Disease. 2020;74(1):331‐343. doi:10.3233/Jad‐190961
Ali F, Whitwell JL, Martin PR, et al. [(18)F] AV‐1451 uptake in corticobasal syndrome: the influence of beta‐amyloid and clinical presentation. J Neurol. 2018;265(5):1079‐1088. doi:10.1007/s00415‐018‐8815‐x
Smith R, Scholl M, Widner H, et al. In vivo retention of (18)F‐AV‐1451 in corticobasal syndrome. Neurology. 2017;89(8):845‐853. doi:10.1212/WNL.0000000000004264
Sha SJ, Ghosh PM, Lee SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8. doi:10.1186/s13195‐014‐0093‐y
Jack CR, Bennett DA, Blennow K, et al. NIA‐AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562. doi:10.1016/j.jalz.2018.02.018
Scholl M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18‐33. doi:10.1016/j.mcn.2018.12.001
Ashton NJ, Scholl M, Heurling K, et al. Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomark Med. 2018;12(7):799‐812. doi:10.2217/bmm‐2017‐0433
Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid‐beta biomarkers for Alzheimer's disease. Nature. 2018;554(7691):249‐254. doi:10.1038/nature25456
Schindler SE, Bollinger JG, Ovod V, et al. High‐precision plasma beta‐amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647‐e1659. doi:10.1212/WNL.0000000000008081
Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease‐related beta‐amyloid status. JAMA Neurol. 2019;76(9):1060‐1069. doi:10.1001/jamaneurol.2019.1632
Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387‐397. doi:10.1038/s41591‐020‐0762‐2
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422‐433. doi:10.1016/S1474‐4422(20)30071‐5
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P‐tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379‐386. doi:10.1038/s41591‐020‐0755‐1
Syrjanen JA, Campbell MR, Algeciras‐Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128‐1140. doi:10.1002/alz.12466
Shir D, Graff‐Radford J, Hofrenning EI, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimers Dement. 2022;14(1):e12291. doi:10.1002/dad2.12291
Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid‐beta but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505‐3516. doi:10.1093/brain/awab223
Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):71. doi:10.1186/s13195‐018‐0404‐9ARTN71
Ashton NJ, Leuzy A, Lim YM, et al. Increased plasma neurofilament light chain concentration correlates with severity of post‐mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Com. 2019;7. doi:10.1186/s40478‐018‐0649‐3ARTN5
Simren J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement. 2021;17(7):1145‐1156. doi:10.1002/alz.12283
Perez‐Grijalba V, Romero J, Pesini P, et al. Plasma Abeta42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis. 2019;6(1):34‐41. doi:10.14283/jpad.2018.41
Doecke JD, Perez‐Grijalba V, Fandos N, et al. Total Abeta(42)/Abeta(40) ratio in plasma predicts amyloid‐PET status, independent of clinical AD diagnosis. Neurology. 2020;94(15):e1580‐e1591. doi:10.1212/WNL.0000000000009240
McGrath ER, Beiser AS, O'Donnell A, et al. Blood phosphorylated tau 181 as a biomarker for amyloid burden on brain PET in cognitively healthy adults. J Alzheimers Dis. 2022;87(4):1517‐1526. doi:10.3233/JAD‐215639
Tissot C, LB A, Therriault J, et al. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):69. doi:10.1186/s13195‐021‐00802‐x
Shi Y, Lu X, Zhang L, et al. Potential value of plasma amyloid‐beta, total tau, and neurofilament light for identification of early Alzheimer's disease. ACS Chem Neurosci. 2019;10(8):3479‐3485. doi:10.1021/acschemneuro.9b00095
Park JE, Gunasekaran TI, Cho YH, et al. Diagnostic blood biomarkers in Alzheimer's disease. Biomedicines. 2022;10(1). doi:10.3390/biomedicines10010169
Pilotto A, Parigi M, Bonzi G, et al. Differences between plasma and cerebrospinal fluid p‐tau181 and p‐tau231 in early Alzheimer's disease. J Alzheimers Dis. 2022;87(3):991‐997. doi:10.3233/JAD‐215646
Mielke MM, Hagen CE, Xu J, et al. Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography. Alzheimers Dement. 2018;14(8):989‐997. doi:10.1016/j.jalz.2018.02.013
Brickman AM, Manly JJ, Honig LS, et al. Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study. Alzheimers Dement. 2021;17(8):1353‐1364. doi:10.1002/alz.12301
Morrison MS, Aparicio HJ, Blennow K, et al. Ante‐mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. Brain. 2022;145(10):3546‐3557. doi:10.1093/brain/awac175
Mielke MM, Syrjanen JA, Blennow K, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252‐e260. doi:10.1212/WNL.0000000000007767
Jabbari E, Holland N, Chelban V, et al. Diagnosis across the spectrum of progressive supranuclear palsy and Corticobasal syndrome. JAMA Neurol. 2020;77(3):377‐387. doi:10.1001/jamaneurol.2019.4347
Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho‐tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231‐e1239. doi:10.1212/WNL.0000000000005261
Benussi A, Ashton NJ, Karikari TK, et al. Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis. 2020;77(3):1129‐1141. doi:10.3233/JAD‐200608
Baiardi S, Quadalti C, Mammana A, et al. Diagnostic value of plasma p‐tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14(1):153. doi:10.1186/s13195‐022‐01093‐6
Alcolea D, Vilaplana E, Suarez‐Calvet M, et al. CSF sAPPbeta, YKL‐40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017;89(2):178‐188. doi:10.1212/WNL.0000000000004088
VandeVrede L, La Joie R, Thijssen EH, et al. Evaluation of plasma phosphorylated Tau217 for differentiation between Alzheimer disease and frontotemporal lobar degeneration subtypes among patients with corticobasal syndrome. JAMA Neurol. 2023;80(5):495‐505. doi:10.1001/jamaneurol.2023.0488
Benedet AL, Leuzy A, Pascoal TA, et al. Stage‐specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain. 2020;143:3793‐3804. doi:10.1093/brain/awaa342
Marks JD, Syrjanen JA, Graff‐Radford J, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021;13(1):199. doi:10.1186/s13195‐021‐00944‐y
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695‐699. doi:10.1111/j.1532‐5415.2005.53221.x
Martinez‐Martin P, Gil‐Nagel A, Gracia LM, Gomez JB, Martinez‐Sarries J, Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. The cooperative multicentric group. Mov Disord. 1994;9(1):76‐83. doi:10.1002/mds.870090112
Shewan CM, Kertesz A. Reliability and validity characteristics of the Western Aphasia Battery (WAB). J Speech Hear Disord. 1980;45(3):308‐324. doi:10.1044/jshd.4503.308
Whitwell JL, Martin P, Graff‐Radford J, et al. The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimers Dement. 2019;15(5):675‐685. doi:10.1016/j.jalz.2018.12.016
Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross‐correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12(1):26‐41. doi:10.1016/j.media.2007.06.004
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839‐851. doi:10.1016/j.neuroimage.2005.02.018
Schwarz CG, Gunter JL, Ward CP, et al. The Mayo Clinic Adult life span template: better quantification across the life span. Alzheimer Dementia. 2017;13(7S_Part_2). doi:10.1016/j.jalz.2017.06.2396
Jack CR Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316‐2325. doi:10.1001/jama.2019.7437
Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13(3):205‐216. doi:10.1016/j.jalz.2016.08.005
Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739‐752. doi:10.1016/S1474‐4422(21)00214‐3
Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer's disease‐related features compared to CSF and plasma p‐tau biomarkers. EMBO Mol Med. 2021;13(8):e14398. doi:10.15252/emmm.202114398
Tissot C, Therriault J, Kunach P, et al. Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau‐PET. EBioMedicine. 2022;76:103837. doi:10.1016/j.ebiom.2022.103837
Barthelemy NR, Li Y, Joseph‐Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med. 2020;26(3):398‐407. doi:10.1038/s41591‐020‐0781‐z
Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551‐1567. doi:10.1093/brain/aww027
Benvenutto A, Guedj E, Felician O, et al. Clinical phenotypes in corticobasal syndrome with or without amyloidosis biomarkers. J Alzheimers Dis. 2020;74(1):331‐343. doi:10.3233/JAD‐190961
Olsson B, Portelius E, Cullen NC, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318‐325. doi:10.1001/jamaneurol.2018.3746
Hansson O, Janelidze S, Hall S, et al. Blood‐based NfL a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930‐937. doi:10.1212/Wnl.0000000000003680
Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci. 2001;183(1):95‐98. doi:10.1016/s0022‐510x(00)00480‐9
Mitani K, Furiya Y, Uchihara T, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998;245(1):44‐46. doi:10.1007/s004150050173
Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M. Decreased beta‐amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005;237(1‐2):61‐65. doi:10.1016/j.jns.2005.05.015
Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau‐related pathology. Biochem Biophys Res Commun. 1997;236(2):262‐264. doi:10.1006/bbrc.1997.6908
Sanchez E, Wilkinson T, Coughlan G, et al. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario neurodegenerative disease research initiative. Alzheimers Dement. 2024;20(3):1753‐1770. doi:10.1002/alz.13560
Kivisakk P, Carlyle BC, Sweeney T, et al. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front Neurol. 2023;14:1069411. doi:10.3389/fneur.2023.1069411
Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia. J Neurol Neurosurg Psychiatry. 2022;93(6):651‐658. doi:10.1136/jnnp‐2021‐327788
Mila‐Aloma M, Ashton NJ, Shekari M, et al. Plasma p‐tau231 and p‐tau217 as state markers of amyloid‐beta pathology in preclinical Alzheimer's disease. Nat Med. 2022;28(9):1797‐1801. doi:10.1038/s41591‐022‐01925‐w